Dec 28, 2025 • MarketBeat
SOMEWHAT-BULLISH
Exchange Traded Concepts LLC Sells 15,265 Shares of Arrowhead Pharmaceuticals, Inc. $ARWR
Exchange Traded Concepts LLC reduced its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 33.0% in the third quarter, selling 15,265 shares. Institutional investors and hedge funds have shown mixed activity, with several increasing their positions in the biotechnology company. Analysts maintain a "Moderate Buy" consensus rating with an average price target of $61.89, while company insiders have been significant sellers.
Dec 27, 2025 • MarketBeat
SOMEWHAT-BULLISH
Texas Permanent School Fund Corp Buys Shares of 19,104 Arrowhead Pharmaceuticals, Inc. $ARWR
Texas Permanent School Fund Corp recently acquired 19,104 shares of Arrowhead Pharmaceuticals, Inc. (NASDAQ:ARWR), valued at approximately $302,000, marking a new position for the institutional investor. This purchase contributes to a total institutional ownership of about 62.61% for the company, despite recent insider selling. Analysts maintain a "Moderate Buy" rating for ARWR, with an average price target of $61.89, and some firms raising their targets significantly.
Dec 26, 2025 • MarketBeat
SOMEWHAT-BULLISH
Voya Investment Management LLC Has $4.74 Million Stock Position in Arrowhead Pharmaceuticals, Inc. $ARWR
Voya Investment Management LLC significantly increased its stake in Arrowhead Pharmaceuticals (NASDAQ:ARWR) by 158.2%, now owning 137,516 shares valued at $4.74 million. Institutional investors collectively hold 62.61% of the company, while several analysts have raised their price targets, indicating a "Moderate Buy" consensus. However, company insiders have recently been net sellers, offloading shares worth $23.67 million.
Dec 25, 2025 • Simply Wall Street
SOMEWHAT-BULLISH
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Status for Plozasiran and Redemplo Launch
Arrowhead Pharmaceuticals (ARWR) recently received FDA Breakthrough Therapy designation for plozasiran and launched Redemplo, significantly boosting its stock. Despite a recent surge in share price, the company's valuation is deemed overvalued by Simply Wall St, with a narrative fair value of $64.08 against its current trading price of $70.11. The article suggests investors consider potential risks like disappointing Phase 3 data for plozasiran or slow Redemplo uptake.
Dec 24, 2025 • Investing.com
NEUTRAL
Arrowhead Pharma director Vakiener sells $679k in stock
Victoria Vakiener, a director at Arrowhead Pharmaceuticals (NASDAQ:ARWR), sold 9,940 shares of common stock totaling $679,491 on December 19, 2025, through a pre-arranged 10b5-1 trading plan. The sales occurred across three transactions with prices ranging from $66.63 to $68.39, just below the stock's 52-week high, leaving Vakiener with 35,723 directly owned shares. This comes amidst other positive company news, including the launch of a new drug, Redemplo, and several analyst price target increases.
Dec 24, 2025 • Sahm
SOMEWHAT-BEARISH
Assessing Arrowhead Pharmaceuticals (ARWR) Valuation After FDA Breakthrough Status for Plozasiran and Redemplo Launch
Arrowhead Pharmaceuticals, Inc. (ARWR) recently received FDA Breakthrough Therapy designation for plozasiran and launched Redemplo, significantly impacting its stock. Despite a 58.4% 30-day share price return and 256.8% year-to-date, the five-year return is negative, showing recent sentiment shift. The article questions whether these positive developments are already factored into its current stock price, which is trading above analyst targets and an estimated fair value of $64.08, suggesting it might be overvalued.